Literature DB >> 33490954

Severe anti-thymocyte globulin-induced cytokine release syndrome in a renal transplant patient.

J Huh1, L Baines2, D Talbot3,4, C MacFie5.   

Abstract

Cytokine release syndrome is a systemic inflammatory response that can be triggered by a variety of factors such as infection or exposure to certain drugs, particularly novel T cell-engaging immunotherapies. Severe cytokine release syndrome as a complication following treatment with anti-thymocyte globulin, although recognised, is not well-reported in the literature. We report the case of a 64-year-old man who developed catastrophic cytokine release syndrome after receiving anti-thymocyte globulin during kidney transplantation. We highlight the importance of prompt recognition of severe cytokine release syndrome with strategies to aid survival in life-threatening cases.
© 2021 Association of Anaesthetists.

Entities:  

Keywords:  anti‐thymocyte globulin; cytokine release syndrome; renal transplant

Year:  2021        PMID: 33490954      PMCID: PMC7805400          DOI: 10.1002/anr3.12092

Source DB:  PubMed          Journal:  Anaesth Rep        ISSN: 2637-3726


  9 in total

Review 1.  Clinical Utility of Extracorporeal Cytokine Hemoadsorption Therapy: A Literature Review.

Authors:  Anthony Bonavia; Andrew Groff; Kunal Karamchandani; Kai Singbartl
Journal:  Blood Purif       Date:  2018-09-03       Impact factor: 2.614

2.  Thymoglobulin-induced severe cardiovascular reaction and acute renal failure in a patient scheduled for orthotopic liver transplantation.

Authors:  S Busani; L Rinaldi; B Begliomini; A Pasetto; M Girardis
Journal:  Minerva Anestesiol       Date:  2006-04       Impact factor: 3.051

3.  Rabbit antithymocyte globulin versus basiliximab in renal transplantation.

Authors:  Daniel C Brennan; John A Daller; Kathleen D Lake; Diane Cibrik; Domingo Del Castillo
Journal:  N Engl J Med       Date:  2006-11-09       Impact factor: 91.245

4.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

5.  A Double-Blind, Double-Dummy, Flexible-Design Randomized Multicenter Trial: Early Safety of Single- Versus Divided-Dose Rabbit Anti-Thymocyte Globulin Induction in Renal Transplantation.

Authors:  R B Stevens; L E Wrenshall; C D Miles; A C Farney; T Jie; J P Sandoz; T H Rigley; A Osama Gaber
Journal:  Am J Transplant       Date:  2016-03-07       Impact factor: 8.086

Review 6.  Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?

Authors:  Catalin Constantinescu; Sergiu Pasca; Tiberiu Tat; Patric Teodorescu; Catalin Vlad; Sabina Iluta; Delia Dima; Dana Tomescu; Ecaterina Scarlatescu; Alina Tanase; Olafur Eysteinn Sigurjonsson; Anca Colita; Hermann Einsele; Ciprian Tomuleasa
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

Review 7.  Toxicity and management in CAR T-cell therapy.

Authors:  Challice L Bonifant; Hollie J Jackson; Renier J Brentjens; Kevin J Curran
Journal:  Mol Ther Oncolytics       Date:  2016-04-20       Impact factor: 7.200

Review 8.  Cytokine release syndrome.

Authors:  Alexander Shimabukuro-Vornhagen; Philipp Gödel; Marion Subklewe; Hans Joachim Stemmler; Hans Anton Schlößer; Max Schlaak; Matthias Kochanek; Boris Böll; Michael S von Bergwelt-Baildon
Journal:  J Immunother Cancer       Date:  2018-06-15       Impact factor: 13.751

9.  Antithymocyte globulin-induced refractory hypotension in renal transplantation recipient.

Authors:  Shamim Rafat; Sahu Sandeep; Siddiqui Tasneem; Agarwal Sanjay
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2017 Jul-Sep
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.